National Employer Initiative on

Specialty Drugs & Biopharma

Employer Focused, Employer Driven

Toolkit Overview

Today’s health benefits professional needs to make critical and informed decisions to better manage the higher cost of specialty drugs inclusive of biopharma drugs and solutions (i.e. biologics, biosimilars, pharmacogenomics, gene therapies).

This toolkit provides guidance, knowledge and access to no-cost resources to support plan performance and cost management efforts, and includes ways to optimize specialty drug use in the medical and pharmacy benefit, make informed decisions on benefit coverage approaches and address PBM transparency issues on pricing, rebates and contracting.

Click here to view this new full report

New Report on Authorized Generics

The Role of Biosimilars a New MBGH Report

Click here to view the full report

Click here to view: National Alliance 2020 Employer Rx Value Report

Click here to access no-cost tools & resources

Click here to view employers' views on the impact of specialty drugs

Click here to view the article: Resolving to Control Drug Costs

Click here to view the article: Resolving to Control Drug Costs

previous arrow
next arrow

2021 Action Brief: Car T-Cell Therapy

The last several years have seen significant growth in the number and utilization of specialty drugs. Cancer immunotherapy, in particular, …

Read More →

2020 Employer RX Value

This report from the National Alliance of Healthcare Purchasers offers insights and a framework for employers on how they can …

Read More →

Resolving to Control Drug Costs

Denise Giambalvo, MBGH Vice President, shares five actions employers can take to create savings for their pharmacy benefits plan and …

Read More →